SageView Advisory Group’s Nephros NEPH Stock Holding History

SageView Advisory Group’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-590	Closed	-$2.88K	–	1778
2025 Q4	$2.88K	Buy	+590	New	+$3.01K	﹤0.01%	2141

Other funds holding NEPH

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

SageView Advisory Group's NEPH Position: Q1 2026 in Review

SageView Advisory Group sold out of Nephros (NEPH) in Q1 2026, closing a stake of 590 shares — an estimated $2.88K sold.

SageView Advisory Group first reported a position in NEPH in Q4 2025 and held it in 1 quarter. The position peaked at $2.88K in Q4 2025. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

SageView Advisory Group reported no remaining Nephros position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 590 Nephros shares in Q1 2026, an estimated $2.88K.
SageView Advisory Group first reported a position in Nephros in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Nephros position peaked at $2.88K in Q4 2025.
27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.